Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

The RA-MAP Consortium: a working model for academia–industry collaboration

A Corrigendum to this article was published on 24 January 2018

This article has been updated


Collaboration can be challenging; nevertheless, the emerging successes of large, multi-partner, multi-national cooperatives and research networks in the biomedical sector have sustained the appetite of academics and industry partners for developing and fostering new research consortia. This model has percolated down to national funding agencies across the globe, leading to funding for projects that aim to realise the true potential of genomic medicine in the 21st century and to reap the rewards of 'big data'. In this Perspectives article, the experiences of the RA-MAP consortium, a group of more than 140 individuals affiliated with 21 academic and industry organizations that are focused on making genomic medicine in rheumatoid arthritis a reality are described. The challenges of multi-partner collaboration in the UK are highlighted and wide-ranging solutions are offered that might benefit large research consortia around the world.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type



Prices may be subject to local taxes which are calculated during checkout

Figure 1: Stratification of patients with rheumatoid arthritis.

Change history

  • 24 January 2018

    In the version of this article originally published, the name of one of the authors, Peter Schulz-Knappe, was incorrectly given as Peter Schulze-Knappe. In addition, Mark Coles and James Butler were erroneously omitted from the list of members of the RA-MAP Consortium. These errors have now been corrected in the PDF and HTML versions of the article.


  1. Jones, A. & Clifford, L. Drug discovery alliances. Nat. Rev. Drug Discov. 4, 807–808 (2005).

    Article  CAS  Google Scholar 

  2. Barnes, M. R. et al. Lowering industry firewalls: pre-competitive informatics initiatives in drug discovery. Nat. Rev. Drug Discov. 8, 701–708 (2009).

    Article  CAS  Google Scholar 

  3. Yildirim, O., Gottwald, M., Schüler, P. & Michel, M. C. Opportunities and challenges for drug development: public-private partnerships, adaptive designs and big data. Front. Pharmacol. 7, 461 (2016).

    Article  Google Scholar 

  4. Schmeck, B., Bertrams, W., Lai, X. & Vera, J. Systems medicine for lung diseases: phenotypes and precision medicine in cancer, infection, and allergy. Methods Mol. Biol. 1386, 119–133 (2016).

    Article  CAS  Google Scholar 

  5. Stingone, J. A. et al. Big and disparate data: considerations for pediatric consortia. Curr. Opin. Pediatr. 29, 231–239 (2017).

    Article  Google Scholar 

  6. Morrison, M. “A good collaboration is based on unique contributions from each side”: assessing the dynamics of collaboration in stem cell science. Life Sci. Soc. Policy 13, 7 (2017).

    Article  Google Scholar 

  7. Wilan, K. H. Opening up the ivory tower. Cell 129, 847–850 (2007).

    Article  CAS  Google Scholar 

  8. Melese, T., Lin, S. M., Chang, J. L. & Cohen, N. H. Open innovation networks between academia and industry: an imperative for breakthrough therapies. Nat. Med. 15, 502–507 (2009).

    Article  CAS  Google Scholar 

  9. Schleidgen, S., Klingler, C., Bertram, T., Rogowski, W. H. & Marckmann, G. What is personalized medicine: sharpening a vague term based on a systematic literature review. BMC Med. Ethics 14, 55 (2013).

    Article  Google Scholar 

  10. Association of the British Pharmaceutical Industry. Stratified medicine in the NHS: an assessment of the current landscape and implementation challenges for non-cancer applications. ABPI (2014).

  11. Association of the British Pharmaceutical Industry. The stratification of disease for personalised medicines. Research driven recommendations to strengthen a unified UK strategy through a stakeholder alliance. ABPI (2014).

  12. Academy of Medical Sciences. Stratified, personalised or P4 medicine: a new direction for placing the patient at the centre of healthcare and health education. Academy of Medical Science s (2015).

  13. UK Trade and Investment. Unlock your global business potential. UK stratified medicine. GOV.UK (2013).

  14. Medical Research Council. The Medical Research Council stratified medicine research initiatives. MRC (2017).

  15. Peltonen, L. & McKusick, V. A. Genomics and medicine. Dissecting human disease in the postgenomic era. Science 291, 1224–1229 (2001).

    Article  CAS  Google Scholar 

  16. Loscalzo, J., Kohane, I. & Barabasi, A. L. Human disease classification in the postgenomic era: a complex systems approach to human pathobiology. Mol. Syst. Biol. 3, 124 (2007).

    Article  Google Scholar 

  17. Botstein, D. & Risch, N. Discovering genotypes underlying human phenotypes: past successes for Mendelian disease, future approaches for complex disease. Nat. Genet. 33, 228–237 (2003).

    Article  CAS  Google Scholar 

  18. Hirschhorn, J. N. & Daly, M. J. Genome-wide association studies for common diseases and complex traits. Nat. Rev. Genet. 6, 95–108 (2005).

    Article  CAS  Google Scholar 

  19. Giacomini, K. M. et al. Genome-wide association studies of drug response and toxicity: an opportunity for genome medicine. Nat. Rev. Drug Discov. 16, 70 (2017).

    Article  Google Scholar 

  20. Chatterjee, N., Shi, J. & García-Closas, M. Developing and evaluating polygenic risk prediction models for stratified disease prevention. Nat. Rev. Genet. 17, 392–406 (2016).

    Article  CAS  Google Scholar 

  21. Berger, B., Peng, J. & Singh, M. Computational solutions for omics data. Nat. Rev. Genet. 14, 333–346 (2013).

    Article  CAS  Google Scholar 

  22. Hood, L., Balling, R. & Auffray, C. Revolutionizing medicine in the 21st century through systems approaches. Biotechnol. J. 7, 992–1001 (2012).

    Article  CAS  Google Scholar 

  23. Institute for Safe Medication Practices. The five rights: a destination without a map. Institute for Safe Medication Practices (2007).

  24. McInnes, I. B., Buckley, C. D. & Isaacs, J. D. Cytokines in rheumatoid arthritis — shaping the immunological landscape. Nat. Rev. Rheumatol. 12, 63–68 (2016).

    Article  CAS  Google Scholar 

  25. Baretta, Z., Mocellin, S., Goldin, E., Olopade, O. I. & Huo, D. Effect of BRCA germline mutations on breast cancer prognosis: a systematic review and meta-analysis. Medicine (Baltimore) 95, e4975 (2016).

    Article  CAS  Google Scholar 

  26. Bunting, S. F. & Nussenzweig, A. End-joining, translocations and cancer. Nat. Rev. Cancer 13, 443–454 (2013).

    Article  CAS  Google Scholar 

  27. Lieber, M. R. Mechanisms of human lymphoid chromosomal translocations. Nat. Rev. Cancer 16, 387–398 (2016).

    Article  CAS  Google Scholar 

  28. Slamon, D. J. et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244, 707–712 (1989).

    Article  CAS  Google Scholar 

  29. Pauletti, G., Godolphin, W., Press, M. F. & Slamon, D. J. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 13, 63–72 (1996).

    CAS  PubMed  Google Scholar 

  30. Maemondo, M. et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med. 362, 2380–2388 (2010).

    Article  CAS  Google Scholar 

  31. Slamon, D. J. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783–792 (2001).

    Article  CAS  Google Scholar 

  32. Khagi, Y., Kurzrock, R. & Patel, S. P. Next generation predictive biomarkers for immune checkpoint inhibition. Cancer Metastasis Rev. 36, 179–190 (2017).

    Article  CAS  Google Scholar 

  33. Siniard, R. C. & Harada, S. Immunogenomics: using genomics to personalize cancer immunotherapy. Virchows Arch. 471, 209–219 (2017).

    Article  CAS  Google Scholar 

  34. Ramamurthy, C., Godwin, J. L. & Borghaei, H. Immune checkpoint inhibitor therapy: what line of therapy and how to choose? Curr. Treat. Options Oncol. 18, 33 (2017).

    Article  Google Scholar 

  35. Medical Research Council. MRC Strategic Review of Human Immunology. MRC (2007).

  36. Gerlag, D. et al. EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis. Ann. Rheum. Dis. 71, 638–641 (2012).

    Article  Google Scholar 

  37. Innovative Medicines Initiative. The IMI funding model. IMI (2017).

  38. Johnson, W. E., Rabinovic, A. & Li, C. Adjusting batch effects in microarray expression data using Empirical Bayes methods. Biostatistics 8, 118–127 (2007).

    Article  Google Scholar 

  39. Herzinger, S. et al. SmartR: an open-source platform for interactive visual analytics for translational research data. Bioinformatics 33, 2229–2231 (2017).

    Article  CAS  Google Scholar 

Download references


The programme of research described in this Perspectives article was funded by the Medical Research Council (MRC), UK. The RA-MAP Consortium would particularly like to thank members of the MRC Immunity and Inflammation Stratified Medicine Steering Group and officers of the MRC, who have supported the work of the RA-MAP Consortium with unbridled enthusiasm.

Author information

Authors and Affiliations




A.P.C., M.R.B. and J.D.I. wrote the manuscript. A.P.C., S.B., F.B.-C. and A.W.P. researched data for the article. A.P.C., M.R.B., A.B., M.B., S.B., F.B.-C., B.A.F., C.S.G., P.E., M.E.R., N.G., R.H., S.H., M.F.M., I.B.M., S.R., A.W.P., F.P., D.P., R.R., A.R., M.A.S., D.S., B.T. and J.D.I. provided substantial contributions to discussions of content. A.P.C., M.R.B., A.B., S.B., F.B.-C., C.C., B.A.F., C.S.G., M.E.R., N.G., R.H., S.H., S.K., M.L., C.L., M.F.M., I.B.M., C.M.M., G.P., S.R., A.W.P., F.P., D.P., A.R., P.S.-K., M.A.S., D.S., P.C.T., B.T., W.T., D.V. and J.D.I. reviewed and/or edited the manuscript before submission.

Corresponding author

Correspondence to Andrew P. Cope.

Ethics declarations

Competing interests

A.P.C. declares that he has acted as a consultant for or received honoraria from BMS, Eisai, GSK, Janssen and Roche. For a full list of competing interests for all co-authors, see Supplementary information S6 (table).

Related links

PowerPoint slides

Supplementary information

Supplementary information S1 (figure)

The RA-MAP Consortium (PDF 95 kb)

Supplementary information S2 (figure)

The RA-MAP Research Programme (PDF 849 kb)

Supplementary information S3 (figure)

Project management and reporting lines (PDF 227 kb)

Supplementary information S4 (figure)

RA-MAP core technologies (PDF 73 kb)

Supplementary information S5 (figure)

Managing 'big data' (PDF 800 kb)

Supplementary information S6 (table)

Contributing authors and their competing interests (PDF 153 kb)

Supplementary information S7 (box)

RA-MAP Consortium Membership (2012 – current) (PDF 266 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cope, A., Barnes, M., Belson, A. et al. The RA-MAP Consortium: a working model for academia–industry collaboration. Nat Rev Rheumatol 14, 53–60 (2018).

Download citation

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research